A detailed history of National Bank Of Canada transactions in Novavax Inc stock. As of the latest transaction made, National Bank Of Canada holds 938 shares of NVAX stock, worth $7,944. This represents 0.0% of its overall portfolio holdings.

Number of Shares
938
Previous 938 -0.0%
Holding current value
$7,944
Previous $11,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$10.71 - $17.11 $17,007 - $27,170
-1,588 Reduced 62.87%
938 $11,000
Q2 2024

Aug 02, 2024

SELL
$3.89 - $20.97 $1.5 Million - $8.08 Million
-385,518 Reduced 99.35%
2,526 $31,000
Q1 2024

May 13, 2024

BUY
$3.76 - $6.02 $1.45 Million - $2.32 Million
385,829 Added 17418.92%
388,044 $1.85 Million
Q4 2023

Feb 06, 2024

SELL
$4.8 - $7.67 $299,246 - $478,170
-62,343 Reduced 96.57%
2,215 $10,000
Q3 2023

Oct 10, 2023

SELL
$6.81 - $9.74 $5.34 Million - $7.64 Million
-784,287 Reduced 92.39%
64,558 $467,000
Q2 2023

Jul 26, 2023

BUY
$6.67 - $9.52 $3.37 Million - $4.82 Million
505,970 Added 147.57%
848,845 $6.31 Million
Q1 2023

Apr 12, 2023

SELL
$5.76 - $12.48 $807,782 - $1.75 Million
-140,240 Reduced 29.03%
342,875 $2.38 Million
Q4 2022

Jan 24, 2023

BUY
$8.86 - $25.04 $4.27 Million - $12.1 Million
481,780 Added 36088.39%
483,115 $0
Q3 2022

Oct 13, 2022

BUY
$18.2 - $76.12 $3,276 - $13,701
180 Added 15.58%
1,335 $24,000
Q2 2022

Jul 28, 2022

SELL
$36.28 - $75.29 $77,494 - $160,819
-2,136 Reduced 64.9%
1,155 $59,000
Q1 2022

May 05, 2022

BUY
$69.73 - $142.9 $129,000 - $264,365
1,850 Added 128.38%
3,291 $242,000
Q4 2021

Jan 24, 2022

BUY
$134.56 - $217.97 $193,900 - $314,094
1,441 New
1,441 $206,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $662M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track National Bank Of Canada Portfolio

Follow National Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

News

Stay updated on National Bank Of Canada with notifications on news.